Dream-hf phase 3 trial results for mesoblast cell therapy in heart failure published in journal of the american college of cardiology (jacc)

Single intra-myocardial intervention with rexlemestrocel-l reduced cardiovascular death, myocardial infarction or stroke over mean follow-up of 30 months in high-risk patients with chronic heart failure single intra-myocardial intervention with rexlemestrocel-l reduced cardiovascular death, myocardial infarction or stroke over mean follow-up of 30 months in high-risk patients with chronic heart failure
MESO Ratings Summary
MESO Quant Ranking